Agilent Technologies Past Earnings Performance
Past criteria checks 6/6
Agilent Technologies has been growing earnings at an average annual rate of 10.6%, while the Life Sciences industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 6.7% per year. Agilent Technologies's return on equity is 23.9%, and it has net margins of 21.7%.
Key information
10.6%
Earnings growth rate
12.1%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 6.7% |
| Return on equity | 23.9% |
| Net Margin | 21.7% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
With EPS Growth And More, Agilent Technologies (NYSE:A) Makes An Interesting Case
Sep 23
Agilent Technologies' (NYSE:A) Profits May Not Reveal Underlying Issues
Sep 09Agilent: A 'Buy' Due To Growing Biopharma, PFAS, And Semi
Aug 23A Look At The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Aug 14Agilent: Making A Move To Ignite Some Growth
Jul 25Agilent Technologies (NYSE:A) Has A Pretty Healthy Balance Sheet
Jul 15Is Agilent A Buy Before Earnings? Examining The Pros And Cons
May 23Should You Investigate Agilent Technologies, Inc. (NYSE:A) At US$154?
May 22Subdued Growth No Barrier To Agilent Technologies, Inc.'s (NYSE:A) Price
May 07These 4 Measures Indicate That Agilent Technologies (NYSE:A) Is Using Debt Reasonably Well
Apr 05Agilent Technologies: Cash Flow Returns On Investments And Conventional All Point To A Hold
Mar 12Agilent Technologies Hit A Homerun
Dec 24Agilent: A Wide Moat Company Expected To Return To Growth In 2024 (Rating Upgrade)
Dec 08Agilent Technologies (NYSE:A) Seems To Use Debt Quite Sensibly
Dec 07Agilent Technologies: Looking Undervalued Heading Into Earnings
Nov 17Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Oct 26Agilent: Dips Into GARP Territory, Shares At A Crucial Spot On The Chart
Sep 26Is It Too Late To Consider Buying Agilent Technologies, Inc. (NYSE:A)?
Sep 08Agilent Technologies (NYSE:A) Seems To Use Debt Quite Sensibly
Aug 21Calculating The Fair Value Of Agilent Technologies, Inc. (NYSE:A)
Jul 23Agilent Technologies - A Wealth Compounder 30% Below Its Highs
Jul 13Here's Why We Think Agilent Technologies (NYSE:A) Might Deserve Your Attention Today
Jul 10What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
May 28Agilent Technologies Stock: Starting To Look Appealing
May 25These 4 Measures Indicate That Agilent Technologies (NYSE:A) Is Using Debt Safely
Apr 17Calculating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Apr 03Here's Why We Think Agilent Technologies (NYSE:A) Might Deserve Your Attention Today
Mar 21Revenue & Expenses Breakdown
How Agilent Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 6,497 | 1,413 | 1,764 | 456 |
| 30 Apr 24 | 6,591 | 1,242 | 1,518 | 465 |
| 31 Jan 24 | 6,735 | 1,236 | 1,553 | 478 |
| 31 Oct 23 | 6,833 | 1,240 | 1,578 | 481 |
| 31 Jul 23 | 6,994 | 1,133 | 1,281 | 486 |
| 30 Apr 23 | 7,040 | 1,351 | 1,579 | 484 |
| 31 Jan 23 | 6,930 | 1,323 | 1,585 | 473 |
| 31 Oct 22 | 6,848 | 1,254 | 1,578 | 467 |
| 31 Jul 22 | 6,659 | 1,328 | 1,552 | 464 |
| 30 Apr 22 | 6,527 | 1,263 | 1,548 | 461 |
| 31 Jan 22 | 6,445 | 1,205 | 1,571 | 455 |
| 31 Oct 21 | 6,319 | 1,210 | 1,562 | 441 |
| 31 Jul 21 | 6,142 | 990 | 1,562 | 426 |
| 30 Apr 21 | 5,817 | 925 | 1,464 | 405 |
| 31 Jan 21 | 5,530 | 810 | 1,404 | 396 |
| 31 Oct 20 | 5,339 | 719 | 1,395 | 397 |
| 31 Jul 20 | 5,223 | 691 | 1,377 | 398 |
| 30 Apr 20 | 5,236 | 683 | 1,446 | 407 |
| 31 Jan 20 | 5,236 | 764 | 1,405 | 406 |
| 31 Oct 19 | 5,163 | 1,071 | 1,358 | 404 |
| 31 Jul 19 | 5,090 | 1,072 | 1,343 | 406 |
| 30 Apr 19 | 5,019 | 1,117 | 1,290 | 402 |
| 31 Jan 19 | 4,987 | 1,140 | 1,301 | 395 |
| 31 Oct 18 | 4,914 | 316 | 1,322 | 387 |
| 31 Jul 18 | 4,809 | 298 | 1,284 | 372 |
| 30 Apr 18 | 4,720 | 237 | 1,269 | 362 |
| 31 Jan 18 | 4,616 | 196 | 1,235 | 354 |
| 31 Oct 17 | 4,472 | 684 | 1,205 | 341 |
| 31 Jul 17 | 4,394 | 633 | 1,173 | 330 |
| 30 Apr 17 | 4,324 | 582 | 1,167 | 329 |
| 31 Jan 17 | 4,241 | 509 | 1,159 | 326 |
| 31 Oct 16 | 4,202 | 462 | 1,174 | 325 |
| 31 Jul 16 | 4,126 | 476 | 1,184 | 324 |
| 30 Apr 16 | 4,096 | 465 | 1,175 | 317 |
| 31 Jan 16 | 4,040 | 466 | 1,170 | 317 |
| 31 Oct 15 | 4,038 | 438 | 1,189 | 327 |
| 31 Jul 15 | 4,046 | 306 | 1,189 | 340 |
| 30 Apr 15 | 4,041 | 256 | 1,184 | 347 |
| 31 Jan 15 | 4,066 | 204 | 1,196 | 353 |
| 31 Oct 14 | 4,048 | 232 | 1,199 | 358 |
| 31 Jul 14 | 4,723 | 435 | 1,325 | 434 |
| 30 Apr 14 | 5,366 | 540 | 1,490 | 518 |
| 31 Jan 14 | 6,110 | 666 | 1,654 | 604 |
| 31 Oct 13 | 3,894 | 225 | 1,184 | 337 |
Quality Earnings: A has high quality earnings.
Growing Profit Margin: A's current net profit margins (21.7%) are higher than last year (16.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A's earnings have grown by 10.6% per year over the past 5 years.
Accelerating Growth: A's earnings growth over the past year (24.7%) exceeds its 5-year average (10.6% per year).
Earnings vs Industry: A earnings growth over the past year (24.7%) exceeded the Life Sciences industry -11.3%.
Return on Equity
High ROE: A's Return on Equity (23.9%) is considered high.